Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.
Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 8, 2022 | Post-IPO Debt | $45M | — | — | — | Detail |
Jul 30, 2021 | IPO | $73.30M | — | — | — | Detail |
Dec 10, 2020 | Series E | $69M | — | — | — | Detail |
Feb 7, 2018 | Series Unknown | $53M | 9 | Bossa Ventures Cathay Venture GeneScience Pharmaceuticals Shire | — | Detail |
Sep 9, 2017 | Series D | $39M | 3 | GV | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bossa Ventures | Yes | Series Unknown |
Cathay Venture | Yes | Series Unknown |
GeneScience Pharmaceuticals | Yes | Series Unknown |
Shire | Yes | Series Unknown |
Incube Ventures | Yes | Series A |
AstraZeneca | — | Series Unknown |
GV | — | Series Unknown |
Novartis | — | Series Unknown |
Ping An Ventures | — | Series Unknown |
Virtus Inspire Ventures | — | Series Unknown |